NCT01172418View on ClinicalTrials.gov

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Transplant; Failure, Kidney
Interventions
DRUG

Alemtuzumab

Alemtuzumab used as part of combined Induction.

DRUG

Daclizumab

Daclizumab used as part of combined induction.

DRUG

Thymoglobulin

Thymoglobulin used as part of combined induction.

Trial Locations (1)

33136

University of Miami Miller School of Medicine, Miami

All Listed Sponsors
lead

University of Miami

OTHER

NCT01172418 - Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols | Biotech Hunter | Biotech Hunter